rimegepant (Nurtec ODT)
Jump to navigation
Jump to search
Indications
Pharmacokinetics
- gepants able to cross the blood brain barrier
Adverse effects
Mechanism of action
- CGRP receptor antagonist
- gepants do not cause vasoconstriction
More general terms
References
- ↑ 1.0 1.1 George J. Oral CGRP Inhibitor Helps Relieve Migraine Attack About 20% report being pain-free within 2 hours. MedPage Today. April 26, 2018 https://www.medpagetoday.com/meetingcoverage/aan/72559
- ↑ 2.0 2.1 Lipton RB, Croop R, Stock EG et al Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31291516 Clinical Trial.
- ↑ 3.0 3.1 Croop R, Goadsby PJ, Stock DA et al Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737-745. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31311674 Clinical Trial.
- ↑ 4.0 4.1 George J First Drug Approved for Acute and Preventive Migraine Treatment. Rimegepant becomes first oral CGRP antagonist to earn nod for migraine prevention. MedPage Today May 28, 2021 https://www.medpagetoday.com/neurology/migraines/92837
- ↑ 5.0 5.1 Windle ML Rapid Rx Quiz: Headache Medications Medscape. Sept 12, 2022 https://reference.medscape.com/viewarticle/980181